Phase I/II study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with relapsed/refractory CLL and Richter's transformation Meeting Abstract
| Authors: | Mato, A. R.; Svoboda, J.; Prak, E. T. L.; Schuster, S. J.; Tsao, P.; Dorsey, C.; Becker, P. S.; Brander, D. M.; Nasta, S. D.; Landsburg, D. J.; King, C. M.; Morrigan, B.; Kennard, K.; Roeker, L. E.; Zelenetz, A. D.; Purdom, M.; Paskalis, D.; Sportelli, P.; Miskin, H. P.; Weiss, M. S.; Shadman, M. |
| Abstract Title: | Phase I/II study of umbralisib (TGR-1202) in combination with ublituximab (TG-1101) and pembrolizumab in patients with relapsed/refractory CLL and Richter's transformation |
| Meeting Title: | 60th Annual Meeting of the American Society of Hematology (ASH) |
| Journal Title: | Blood |
| Volume: | 132 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2018 Dec 1-4 |
| Meeting Location: | San Diego, CA |
| ISSN: | 0006-4971 |
| Publisher: | American Society of Hematology |
| Date Published: | 2018-11-29 |
| Language: | English |
| ACCESSION: | WOS:000454837601006 |
| PROVIDER: | wos |
| DOI: | 10.1182/blood-2018-99-117526 |
| Notes: | Meeting Abstract: 297 -- Source: Wos |
Altmetric
Citation Impact
BMJ Impact Analytics
